Deep Lens, an AI-enabled clinical trial recruitment platform, has closed a $14 million Series A round led by Northpond Ventures, with participation from existing investors Rev1 Ventures, Sierra Ventures, and Tamarind-Hill Partners.
The company's VIPER platform enables clinicians to identify eligible patients for clinical trials at the point of diagnosis, which can help fast-track trial enrollment and potentially shorten the duration of the trial. The technology was originally developed for research purposes, and was the de-facto platform for global oncology studies.
The funding will be used for product development, and to build up sales and marketing capabilities. The Series A follows on three months after a $3.5 million seed round.